

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 431 668 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: **15.02.95** (51) Int. Cl.⁶: **C12N 15/86, C07H 21/04, C12N 5/10, A61K 39/245, //A61K39/255, A61K39/17**
- (21) Application number: **90203076.6**
- (22) Date of filing: **21.11.90**

(54) **Recombinant herpesvirus of turkeys and live vector vaccines derived thereof.**

(30) Priority: **04.12.89 EP 89203071**

(43) Date of publication of application:
12.06.91 Bulletin 91/24

(45) Publication of the grant of the patent:
15.02.95 Bulletin 95/07

(84) Designated Contracting States:
BE CH DE ES FR GB GR IT LI NL SE

(56) References cited:
WO-A-88/07088
WO-A-89/01040

(73) Proprietor: **Akzo Nobel N.V.**
Velperweg 76
NL-6824 BM Arnhem (NL)

(72) Inventor: **Sondermeijer, Paulus Jacobus Antonius**
Mahonie 21
NL-5831 RN Boxmeer (NL)
Inventor: **Claessens, Johannes Antonius Joseph**
Mees 25

NL-5831 MR Boxmeer (NL)
Inventor: **Mockett, Albert Phillip Adrian**
15 Chichester Way,
Perry
Huntington,
Cames PE18 OD5 (GB)

(74) Representative: **Hermans, Franciscus G.M. et al**
Patent Department
AKZO NOBEL N.V.
Pharma Division
P.O. Box 20
NL-5340 BH Oss (NL)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

The present invention is concerned with a recombinant Herpesvirus of Turkeys (HVT) containing a heterologous nucleic acid sequence introduced into an insertion-region of the HVT genome, a nucleic acid sequence comprising a heterologous gene flanked by DNA sequences derived from said insertion-region of the HVT genome, a plasmid comprising said nucleic acid sequence, a process for the preparation of a recombinant HVT, a cell culture infected with a recombinant HVT, a vaccine comprising recombinant HVT as well as a process for the preparation of such a vaccine and antiserum comprising antibodies directed against a recombinant HVT.

Marek's disease (MD) is an oncogenic lymphoproliferative disorder of chickens which results in T-cell lymphomas and peripheral nerve demyelination and is a major cause of economic loss to the poultry industry.

Marek's disease virus (MDV) has been identified as the etiologic agent of MD.

A prototype MD vaccine consists of Herpesvirus of Turkeys (HVT), a serotype 3 MD virus originally isolated from turkeys. Its lack of pathogenicity, oncogenicity, its good replication in vivo and in vitro, availability as cell-free and cell-associated preparations and high protective efficacy have established HVT as a very successful and widely used safe vaccine for the effective control of Marek's disease in poultry.

At present, in general, animals can be protected against infection of pathogenic micro-organisms with live or inactivated vaccines or by vaccines derived from subunits of the relevant pathogens.

However, these types of vaccines may suffer from a number of drawbacks. Using attenuated live viral vaccines always involves the risk of inoculating animals with inadequately attenuated pathogenic micro-organisms. In addition the attenuated viruses may revert to a virulent state resulting in disease of the inoculated animals and the possible spread of the pathogen to other animals.

Inactivated vaccines generally induce only a low level of immunity, requiring additional immunizations. Furthermore, the neutralization- inducing antigenic determinants of the viruses may become altered by the inactivation treatment, decreasing the protective potency of the vaccine.

Moreover, a problem with combined live viral vaccines is the mutual influence of the antigenic components resulting in a decrease of the potency of one or more of the constituting components.

A recombinant or naturally derived subunit vaccine also displays a number of disadvantages. First, a polypeptide subunit presented to the immune system as a non-replicating structure often does not elicit long-lasting immunity requiring also the presence of an adjuvant. Secondly, a presentation as a replicating structure can elicit immunity more efficiently than can a presentation as a subunit structure.

It is an object of the present invention to provide a recombinant HVT which can be used not only for the preparation of a vaccine against MD but also against other infectious diseases of poultry, which obviates any potential risk associated with the use of a live attenuated pathogen as a vaccine, which stimulates both the humoral and cellular immune system in a potent way without the explicit need of an adjuvant and which offers the possibility of a multivalent vaccine without the risk of adverse mutual interference of different antigenic components.

A recombinant HVT containing heterologous nucleic acid sequences is disclosed in Patent Application WO 88/07088. The gene of interest is inserted within the region encoding the viral thymidine kinase gene indicating that this part of the viral genome is not essential for viral replication. The thymidine kinase gene is located within the UI region of the genome. No other non-essential parts of the HVT genome have been identified.

According to the present invention such a recombinant HVT is characterized in that it contains a heterologous nucleic acid sequence encoding a polypeptide heterologous to HVT, said nucleic acid sequence being introduced in an insertion-region of the HVT genome which corresponds with the genomic region from the end of ORF-1 up to and including ORF-5 as shown in figure 1 and located within a DNA fragment of the HVT genome having a restriction enzyme map essentially defined by figure 1.

The recombinant HVT according to the invention can be derived from any HVT strain, e.g. PB-THV1 (commercially available from Intervet International) or strain FC126.

The term "recombinant HVT" as used herein denotes infective virus which has been genetically modified by incorporation into the virus genome of a heterologous nucleic acid sequence, i.e. DNA which codes for a gene or part thereof not identical to the nucleic acid sequence of a gene naturally present in HVT.

On infection of a cell by the recombinant HVT, the recombinant HVT expresses the heterologous gene in the form of a heterologous polypeptide.

The term "polypeptide" refers to a molecular chain of amino acids with a biological activity, does not refer to a specific length of the product and if required can be modified in vivo or in vitro, for example by

glycosylation, amidation, carboxylation or phosphorylation; thus inter alia peptides, oligopeptides and proteins are included within the definition of polypeptide.

The prerequisite for a useful recombinant HVT is that the heterologous nucleic acid sequence is incorporated in a permissive position or region of the genomic HVT sequence, i.e. a position or region which can be used for the incorporation of a heterologous sequence without disrupting essential functions of HVT such as those necessary for infection or replication. Such a region is called an insertion-region.

The insertion-region referred to in the present invention has not been previously described for the incorporation of heterologous DNA without disrupting essential functions of HVT. Moreover, no information has been available with regard to the restriction enzyme map of the genomic region of HVT used to incorporate a heterologous DNA sequence as described herein.

The insertion-region used to incorporate a heterologous DNA sequence in order to prepare a recombinant HVT according to the invention is located within a 17,5 kb restriction fragment generated by partial digestion of genomic HVT DNA with the enzyme *Sau3A*.

Said fragment is analyzed in detail by restriction enzyme mapping (figure 1) and essentially corresponds to the *Us* region of the HVT genome, probably including flanking parts of the *IR_s* and *TR_s* structures. The relative positions of the *Us* region and the *IR_s* and *TR_s* structures within the HVT genome are shown by Igarashi et al. (1987).

The insertion-region disclosed herein is located within three contiguous *Xho*I fragments of about 1,2 kb, 3,5 kb and 2,8 kb respectively, and begins at the end of an open reading frame (ORF-1) starting at a position in the HVT genome leftwards of the 1,2 kb *Xho*I fragment (figure 1). Said insertion-region of about 5 kb continues through the ORF's, 2, 3, 4 and 5 including the non-coding sequences in between. DNA sequences corresponding to the insertion-region outlined above can be applied for the insertion of genes into the HVT genome without disrupting essential functions of the virus.

Particularly, ORF-2 and ORF-3 can be applied for the integration of foreign genes.

Preferred insertion sites for foreign genes within ORF-2 and ORF-3 are the unique *Bgl*III restriction sites shown in figure 1.

The β -galactosidase gene is inserted at either of the unique *Bgl*III restriction sites within ORF-2 and ORF-3 resulting in a recombinant virus which is viable and stable and not only replicates in tissue culture but also infects chickens to a comparable extent as the HVT virus from which it has been derived. *E. coli* transformed with plasmids designated pMD07gal or pMD12gal (figure 2), derived by insertion of the β -gal gene into the unique *Bgl*III site of pMD07 and pMD12 which carry the respective *Xho*I fragments as indicated in figure 1, are deposited at the C.N.C.M. of the Institute Pasteur at Paris under accession number I-914 and I-915.

In another example significant parts of the ORF-4 and ORF-5 have been deleted from the HVT genome and replaced by the β -galactosidase marker gene resulting in recombinant viruses comparable with recombinant HVT viruses comprising an insertion of the marker gene in ORF-2 or ORF-3.

It will be understood that for the DNA sequence of the HVT genome, natural variations can exist between individual HVT viruses. These variations may result in deletions, substitutions, insertions, inversions or additions of one or more nucleotides which possibly influence the position of one or more restriction sites, thus affecting the restriction enzyme map shown in figure 1.

Moreover, the potential exists to use genetic engineering technology to bring about above-mentioned variations resulting in a DNA sequence with a restriction enzyme map related to the map shown in figure 1. It is clear that a recombinant HVT comprising a heterologous gene incorporated into an insertion-region located within an HVT genomic region characterized by such a related restriction enzyme map is also included within the scope of the present invention. Furthermore, as the insertion-region identified according to the present invention does not display essential functions, said region can be deleted partially or completely, whereafter a heterologous gene can be incorporated into said deletion. It will be understood that a recombinant HVT comprising a heterologous gene incorporated into a region of the HVT genome corresponding to the insertion-region of the present invention and characterized herein also forms part of the invention.

In summary, the insertion-region essentially defined above characterizes the localization of a region within the HVT genome which can be used to incorporate a heterologous nucleic acid sequence.

It is a preferred object of the present invention to provide a recombinant HVT that contains a heterologous nucleic acid sequence which is incorporated into an insertion-region essentially characterized by the HVT DNA sequence as shown in SEQ ID NO: 1, containing four ORF's. ORF-2, a small open reading frame of 209 amino acids (SEQ ID NO: 2) is located between nucleotide positions 316 and 945 and contains the *Bgl*III restriction site from pMD07 used for the insertion of genes into the HVT genome (Figure 1, SEQ ID NO: 1), thereby indicating that the hypothetical polypeptide encoded for by ORF-2 does not have an

essential function for maintenance of the virus in vivo or in vitro. This also applies for ORF-3, comprising 346 amino acids (SEQ ID NO: 3), which is translated in the reverse orientation between nucleotide positions 1084 and 2124 (complementary), and contains the BglII restriction site which is used in pMD12 for the insertion of genes into the HVT genome (Figure 1, SEQ ID NO: 1). ORF-4 is transcribed towards the IR_s,
 5 between nucleotide positions 2322 and 3170 (complementary, Figure 1, SEQ ID NO: 1) and encodes 282 amino acids (SEQ ID NO: 4) while ORF-5 starts at nucleotide position 3320 and continues up to nucleotide position 4504 (Figure 1, SEQ ID NO: 1) encoding a polypeptide of 394 amino acids (SEQ ID NO: 5).

According to the invention a continuous DNA stretch of the HVT genome of about 5 kb starting after the end of ORF-1 at nucleotide position 82 essentially characterized by the DNA sequence shown in SEQ ID
 10 NO: 1, comprising four open reading frames and non-coding sequences in between, can be applied for the insertion of heterologous genes into the HVT genome without disrupting essential functions of the virus.

Particularly, the DNA stretches between nucleotide positions 316-945, 1084-2124, 2322-3170 and 3320-4504 shown in SEQ ID NO: 1 have been defined for the integration of foreign genes, the unique BglII restriction sites being the most favoured sites for insertion.

It is clear that for the DNA sequence shown in SEQ ID NO: 1, characterizing the insertion-region according to the present invention, natural variations exist between individual HVT viruses resulting in deletions, substitutions, insertions, inversions etc. of one or more nucleotides. These variations can also be brought about by genetic engineering. Recombinant HVT comprising a heterologous gene incorporated into such a region of the HVT genome related but not identical to the insertion-region characterized above, also
 20 is included within the present invention. For example a heterologous gene can be incorporated into a deletion brought about in the nucleic acid sequence of the HVT genome shown in SEQ ID NO: 1. The HVT insertion-region defined herein by the DNA sequence shown in SEQ ID NO: 1 characterizes the localization of a region within the HVT genome which can be used to incorporate a heterologous nucleic acid sequence.

The heterologous nucleic acid sequence to be incorporated into the HVT genome according to the present invention can be derived from any source, e.g. viral, prokaryotic, eukaryotic or synthetic. Said nucleic acid sequence can be derived from a pathogen, preferably an avian pathogen, which after insertion into the HVT genome can be applied to induce immunity against disease. Preferably, nucleic acid sequences derived from Infectious Bronchitis Virus (IBV), Marek's Disease Virus (MDV), Newcastle Disease Virus (NDV), Infectious Bursal Disease Virus (IBDV), Chicken Anaemia Agent (CAA), Reo Virus, Avian Retro
 30 Virus, Fowl Adeno Virus, Turkey Rhinotracheitis Virus, Eimeria species, Salmonella species, Escherichia coli and Mycoplasma gallisepticum are contemplated for incorporation into the insertion-region of the HVT genome.

Furthermore, nucleic acid sequences encoding polypeptides for pharmaceutical or diagnostic applications, in particular immune modulators such as lymphokines, interferons or cytokines, may be incorporated
 35 into said insertion-region.

An essential requirement for the expression of the heterologous nucleic acid sequence in a recombinant HVT is an adequate promotor operably linked to the heterologous nucleic acid sequence. It is obvious to those skilled in the art that the choice of a promotor extends to any eukaryotic, prokaryotic or viral promotor capable of directing gene transcription in cells infected by the recombinant HVT, e.g. promoters derived of
 40 the retroviral long terminal repeat, SV40 or promoters present in HVT.

The technique of in vivo homologous recombination can be used to introduce the heterologous nucleic acid sequence into the HVT genome. This is accomplished by first constructing a recombinant DNA molecule for recombination with HVT. Such a molecule may be derived from any suitable plasmid, cosmid or phage, plasmids being most preferred, and contains a heterologous nucleic acid sequence, if desired
 45 operably linked to a promotor. Said nucleic acid sequence and promotor are introduced into a fragment of genomic HVT DNA containing insertion-region sequences as defined herein subcloned in the recombinant DNA molecule. The insertion-region sequences which flank the heterologous nucleic acid sequence should be of appropriate length as to allow in vivo homologous recombination with the viral HVT genome to occur. If desired, a construct can be made which contains two or more different heterologous nucleic acid
 50 sequences derived from e.g. the same or different pathogens said sequences being flanked by insertion-region sequences of HVT defined herein. Such a recombinant DNA molecule can be employed to produce recombinant HVT which expresses two or more different antigenic polypeptides to provide a multivalent vaccine. Secondly, cells, e.g. chicken embryo fibroblasts (CEF), can be transfected with HVT DNA in the presence of the recombinant DNA molecule containing the heterologous nucleic acid sequence flanked by
 55 appropriate HVT sequences whereby recombination occurs between the insertion-region sequences in the recombinant DNA molecule and the insertion-region sequences in HVT. Recombination can also be brought about by transfecting the infected cells with a nucleic acid sequence containing the heterologous nucleic acid sequence flanked by appropriate flanking insertion-region sequences without recombinant DNA

molecule sequences. Recombinant viral progeny is thereafter produced in cell culture and can be selected for example genotypically or phenotypically, e.g. by hybridization, detecting enzyme activity encoded by a gene co-integrated along with the heterologous nucleic acid sequence or detecting the antigenic heterologous polypeptide expressed by the recombinant HVT immunologically. The selected recombinant HVT can be cultured on a large scale in cell culture whereafter recombinant HVT containing material or heterologous polypeptides expressed by said HVT can be collected therefrom.

According to the present invention a live recombinant HVT expressing one or more different heterologous polypeptides of specific pathogens can be used to vaccinate animals, particularly avian species such as chickens, turkeys, quails pigeons and guinea fowl, susceptible to these pathogens. Vaccination with such a live vector vaccine is preferably followed by replication of the recombinant HVT within the inoculated host, expressing in vivo the heterologous polypeptide along with the HVT polypeptides. The heterologous immunogenic polypeptides will then elicit an immunological response to said polypeptides as well as to HVT itself. If the heterologous polypeptide derived from a specific pathogen can stimulate a protective immune response, then the animal inoculated with a recombinant HVT according to the invention will be immune to subsequent infection by that pathogen as well as to infection by MDV. Thus, a heterologous nucleic acid sequence incorporated into the insertion-region of the HVT genome according to the invention may be continuously expressed in vivo, providing a solid, safe and longlasting immunity to a pathogen.

A recombinant HVT according to the invention containing and expressing one or more different heterologous polypeptides can serve as a monovalent or multivalent vaccine.

A recombinant HVT according to the invention can also be used to prepare an inactivated vaccine.

For administration to animals, the recombinant HVT according to the presentation can be given inter alia by aerosol, drinking water, orally, in ovo inoculation, intradermally, subcutaneously or intramuscularly.

It is a further object of the present invention to produce subunit vaccines, pharmaceutical and diagnostic preparations comprising a heterologous polypeptide expressed by a recombinant HVT according to the invention. This can be achieved by culturing cells infected with said recombinant HVT under conditions that promote expression of the heterologous polypeptide. The heterologous polypeptide may then be purified with conventional techniques to a certain extent depending on its intended use and processed further into a preparation with immunizing, therapeutic or diagnostic activity.

The above described active immunization against specific pathogens will be applied as a protective treatment in healthy animals. It goes without saying that animals already infected with a specific pathogen can be treated with antiserum comprising antibodies evoked by a recombinant HVT according to the invention comprising a heterologous gene derived from the specific pathogen encoding an antigenic polypeptide. Antiserum directed against a recombinant HVT according to the invention can be prepared by immunizing animals, for example poultry, with an effective amount of said recombinant HVT in order to elicit an appropriate immune response. Thereafter the animals are bled and antiserum can be prepared.

Example 1

1. Isolation of subfragments from the Us region of the HVT genome

Chicken embryo fibroblasts (CEF) were infected with virus from HVT vaccine strain PB-THV1 (commercially available from Intervet International, Holland) and incubated for 48 hours in roller bottles until the cultures reached 90% cytopathic effect (CPE). Cells were harvested, washed with phosphate buffered saline (PBS), centrifuged and resuspended in 20 mM Tris-HCl, pH 7.5, 10 mM EDTA at a density of 1 to 5 x 10⁸ cells per ml. SDS was added to 0.5% final concentration and proteinase K (Boehringer) to 200 µg/ml. After 2 hours incubation at 37°C, an additional 100 µg/ml of proteinase K was added and incubation was continued for 1 hour. The solution was extracted twice with a mixture of phenol/chloroform (1:1) and nucleic acids were precipitated with ethanol. Total DNA from infected cells was dissolved in TE (10 mM Tris-HCl, pH 7.5, 1 mM EDTA) at a concentration of 0.5 mg/ml. Ten microgram of the DNA was incubated with 0.5 unit of Sau3A (Promega) for 10' at 37°C in a 100 µl reaction volume according to the conditions recommended by the enzyme supplier. Reaction products were separated on a 0.8% agarose gel and the size fraction between 16 and 20 kb was isolated. Hundred nanograms of these DNA fragments were ligated overnight at +4°C with 1 µg of BamHI/EcoRI digested λEMBL3 DNA (Promega) in 10 µl of 30 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 10 mM DTT, 0.1 mM ATP, adding 1 U of T₄ DNA ligase (Boehringer). After ligation, one tenth of the reaction mixture was digested with BamHI in a 10 µl volume and DNA was packaged in vitro using commercial extracts (Promega). Recombinant phage was plated on appropriate E.coli host strain such as LE392 or K802 at a density of about 100 pfu/plate. Replicas of the dishes were prepared in duplicate using nitrocellulose filters according to Benton & Davis (1978). The first set was

hybridized (Maniatis et al., 1982) with ^{32}P -labelled DNA from uninfected CEF and the second with ^{32}P -labelled DNA from HVT infected cells. After washing and exposure to X-ray film, images of the duplicate filters were superimposed in the correct orientation and several of the plaques giving a signal specifically with the probe made from infected cells, were isolated and phage from it was amplified. One of these candidates, designated λHVT04 , was analyzed in detail by restriction mapping of the 17.5 kb insert (Figure 1). The sequence present in this fragment corresponded essentially to the Us region of the HVT genome, including flanking parts of the repeat structures (Igarashi, et al., 1987).

2. Insertion of β -galactosidase gene into the HVT genome using subfragments of the Us region

10

Two of the XhoI fragments present in the insert of λHVT04 contained a unique BglII restriction site at the proper position in order to allow the in vivo recombination event with intact viral genomic DNA to take place. These two fragments were subcloned from λHVT04 by XhoI digestion and ligation with the plasmid vector pGEM3Z (Promega) digested with Sall. The resulting plasmid constructs pMD07 and pMD12, carrying the XhoI fragments as indicated in figure 1, were linearized by means of the unique BglII restriction site and ligated with a 4.0 kb expression cassette flanked by BamHI sites and containing the β -galactosidase gene from E. coli controlled by the early promoter from SV40. This expression cassette has been derived from pCH110, a plasmid commercially available from Pharmacia, by replacing a 72 bp SphI fragment near the SV40 origin of replication as present in pCH110 by a double stranded synthetic oligonucleotide with the following structure:

20

5' -GGATCCGTCGACCATG-3'

3' -GTACCCTAGGCAGCTG-5'

25

Insertion of the linker between the two SphI restriction sites of pCH110 does not restore the recognition sequence for SphI on either site and creates both a BamHI and Sall site upstream of the SV40 early promoter. Subsequent digestion of this construct with BamHI generates a 4.0 kb expression cassette used above for insertion in the BglII site from pMD07 and pMD12, thereby resulting in the plasmids pMD07gal and pMD12gal for which the restriction maps are shown in figure 2. Linearized DNA of the plasmids pMD07gal and pMD12gal was introduced together with total DNA prepared from HVT infected cells into CEF by a method based on the calcium phosphate DNA precipitation according to Graham and v.d. Eb (1973). Two microgram of plasmid DNA from the constructs containing the β -galactosidase gene flanked by HVT homologous sequences were mixed with 15 μg of DNA from HVT infected cells in a final volume of 560 μl H_2O and added to 750 μl of HBSP (20 mM KCl, 560 mM NaCl, 24 mM glucose, 3 mM Na_2HPO_4 , 100 mM HEPES, pH 7.0). Precipitates were formed by gradually adding 190 μl of 1M CaCl_2 solution and incubating the mixtures at room-temperature for 30 minutes. In the meantime, 15 ml of a suspension of secondary CEF from 10 day old embryos in medium 6/B8, for which the composition is based on Glasgow's modification of Eagle's Minimal Essential Medium supplemented with 2% of foetal calf serum, were seeded in \varnothing 10 cm dishes at a density of 5×10^5 cells per ml. Calcium phosphate precipitated DNA was gently added to the cell suspension and dishes were incubated at 37°C in a humidified incubator containing 5% CO_2 in air. After 5 hours, medium was removed and 10 ml of a solution containing equal volumes of HBSP and 30% glycerol was layered onto the cells. After a one to two minute incubation, the solution was removed, cells were washed with medium 6/B8 and dishes were incubated with fresh medium for 3 to 5 days until viral CPE developed. Plaques that contained recombinant HVT virus expressing β -galactosidase activity were identified by their capacity to convert the substrate Bluogal (Gibco-BRL), a chemical derivative of 5-bromo-4-chloro-3-indolyl- β -D-galactoside, into a blue reaction product. Plates were stained with 0,2 mg/ml of Bluogal freshly dissolved in dimethylsulfoxide and incubated until blue plaques were detected. Transfection with the β -galactosidase derivatives from pMD07 and pMD12, all resulted in a significant (>5) percentage of blue plaques. Positive plaques from the transfection series with pMD07 and pMD12 were picked macroscopically and mixed with fresh CEF in order to amplify the virus. Cells were harvested when CPE was visible and lysates were prepared in Calstab-buffer (74.35 g sucrose, 0.52 g KH_2PO_4 , 2.58 g $\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$ and 0.92 g sodium glutamate per liter of H_2O) including 1% of bovine serum albumin, by sonifying plastic tubes containing the extract in a Vibracell 300 cup horn device for 3 minutes at 15°C . Cell-free virus was plated on fresh CEF for titration and plaques containing blue-staining recombinant HVT virus were detected and amplified as described above. This cycle was repeated until more than 95% of the viral plaques scored positive when staining the cultures with Bluogal. In particular

four clones, designated as A4-1/A10-4 both derived from pMD07 and E1/E2 derived from pMD12, were selected for the preparation of virus stocks which served the vaccination experiments in chickens. In addition, part of the stock was used for the preparation of total DNA from infected CEF. DNA digested with XhoI was run on agarose gels and transferred to nitrocellulose sheets according to Maniatis et al. (1982). Hybridizations of the samples from A4-1/A10-4 and E1/E2 in comparison to XhoI digested DNA of the non-recombinant HVT virus, using the non-disrupted XhoI fragments as probes, indicated the expected increase in size of the original fragments in pMD07 and pMD12 due to the insertion of the β -galactosidase cassette.

The β -galactosidase marker gene was used to show that also ORF-4 and ORF-5 represented a potential insertion region. For this purpose, the 1117 bp SpeI fragment in pMD12 between nucleotide position 2311 in ORF-4 and 3428 in ORF-5, was replaced by a synthetic 16-base double stranded oligomer creating a new and unique Sal I site in pMD12 thereby deleting a significant part of both ORF-4 and ORF-5. The restriction map of this plasmid, designated pMD40, is presented in Figure 3A. The β -galactosidase marker gene used for insertion was derived from pCH110 (Pharmacia) by first exchanging the unique Bam HI site with Sal I and subsequently replacing the 72-bp SphI fragment by a double stranded synthetic linker containing both a Bam HI and Sal I restriction site as described above.

The β -galactosidase marker gene is now located on a 4,0 kb DNA fragment flanked by Sal I sites and can be transferred as such to the newly created Sal I site in pMD40, thereby resulting in plasmid pMD44 (see Fig. 3B).

Linearized DNA of pMD44 is co-transfected with DNA from HVT infected cells into secondary CEF as described above. Plates are incubated until CPE has developed. Staining of the culture dishes with Bluogal identified a significant percentage of HVT plaques expressing β -galactosidase activity.

These results were comparable with initial observations made after insertion of the marker gene in ORF-2 and ORF-3.

Example 2

Vaccination of chickens with recombinant HVT expressing β -galactosidase activity

White leghorn day-old chickens were inoculated i.m. with either 50 or 1000 pfu of the virus stocks A4-1 and E1. An equal dose of the parental HVT vaccine strain PB-THVI was given to the control animals. At day 8 and 15, blood samples were collected and white blood cells were separated on Ficoll/Hypaque gradients. White blood cells were inoculated on to secondary CEF and the number of plaques was determined relative to the number of cells inoculated. The results of these titrations are shown in Table 1 and demonstrate that recombinant HVT virus, containing a β -galactosidase gene inserted in either of the unique BglII restriction sites within each of the XhoI subfragments present in pMD07 and pMD12 respectively, was able to induce viraemias in chickens at comparable times and levels relatively to the non-recombinant PB-THVI vaccine strain. Staining with Bluogal of some of the white blood cell titrations on CEF showed that >90% of the virus recovered from the infected birds still expressed the β -galactosidase gene. In addition, significant ELISA antibody titres to β -galactosidase were demonstrated in the serum samples of individual animals 35 days after inoculation. Therefore, it was concluded that a particular region of the Us from the HVT genome, as defined by the contiguous sequence present in pMD07 and pMD12, can be used for the stable integration of foreign genes without affecting essential functions of the HVT virus such as those necessary for infection and replication. In addition, it could be shown that a foreign gene inserted in this region does express a functional protein which can induce high levels of antibody titres in the serum of infected animals.

Table 1

Viraemia of white blood cells (WBC) induced by recombinant HVT					
Virus	Dose (pfu)	8 days p.v.		15 days p.v.	
		calculated plaques	Nos. cells inoculated ($\times 10^5$)	calculated plaques	Nos. cells inoculated ($\times 10^5$)
A4-1	50	8*	6.8	21	14.7
		1*	1.5	44	35.5
		20	3.2	17	27.5
A4-1	1000	30	5.7	7	28.2
		8*	1.5	20	16.5
		13	1.2	18	30.7
		7*	1.7		
E1	50	95	0.7	14	10.7
		1600	3.3	150	17.2
		170	2.5	55	9.0
		2*	1.8	85	13.7
		1*	2.1	30	13.5
E1	1000	2*	1.8	24	19.2
		1*	1.3	75	30.5
		15	5.2	15	25.0
PB1	50	13	1.7	110	14.5
		26	1.5	130	34.2
		27	3.0	110	14.5
		12	3.7	290	20.2
		6*	2.0	36	8.2
PB1	1000	110	6.5	32	15.5
		185	4.0	600	122.5
		1150	4.7	280	19.5
		65	3.0	345	6.7
		330	3.0	175	27.5

*read 5 days after inoculation of WBC on CEF plates other read after 3 days post inoculation

Example 3

Sequence analysis of part of the Us region of HVT.

The inserts of plasmids pMD07 and pMD12, corresponding to the respective XhoI restriction fragments from the HVT genome as shown in figure 1, were submitted to detailed nucleotide sequence analysis using double stranded DNA preparations in dideoxy chain termination reactions according to Sanger et al. (1977). Priming of the reaction was done from within the SP6 and T7 promotor sites in the pGEM3Z plasmid vector flanking the respective HVT genomic fragments. The analysis was completed by introducing progressive deletions entering the respective fragments in one orientation only. These progressive deletions were introduced using the enzyme Exonuclease- III, a single strand exonuclease only recognizing double stranded DNA and hydrolizing one strand of the duplex in the 3' to 5' orientation. Selecting a restriction site that creates a 5'-overhanging or blunt-ended extremity near the end of the fragment to be analyzed, in combination with a second restriction enzyme generating a 3' single stranded extremity which protects the primer initiation site SP6 or T7 in the plasmid vector from being degraded by the Exonuclease-III, forces the enzyme to remove one strand of the inserted DNA fragment such as present in pMD07 or pMD12. Samples were taken from the reaction mixture at 30 seconds interval and treated according to the procedures described by Henikoff (1984), generating recircularized DNA molecules which are transformed into an appropriate E. coli host strain. Plasmid DNA minipreparations of individual colonies were analyzed by

restriction mapping for the size of the deletion introduced into the original 1.2 and 3.5 kb fragments of pMD07 and pMD12 respectively. A series of candidates containing progressive deletions entering the fragment in one orientation, were analyzed by nucleotide sequencing using the double stranded DNA from mini-preparations in the chain termination reaction. Reaction products were separated on denaturing
 5 acrylamide gels and visualized on X-ray film by autoradiography. Banding patterns were read with a digitizer and data were assembled and analyzed using the shot-gun handler and other software from a Gene-Master workstation (Bio-Rad).

The XhoI restriction fragment adjacent the XhoI fragment present in pMD12 was subcloned from λ HVT04 (Figure 1) into pMD36 and partially sequenced according to the same procedure described above.

10 Example 4

After the identification and detailed analysis of a region within the HVT genome where gene insertions are allowed to be made, a recombinant HVT virus can be constructed with any gene other than the one
 15 encoding β -galactosidase. However, particularly those genes are of interest which encode relevant antigens from both related and non-related avian pathogens. An example of such an application will be described in the following paragraphs. The gene of interest encodes the 157 kd precursor molecule for the peplomer protein of Infectious Bronchitis Virus (IBV), a highly contagious coronavirus of chickens. This glycosylated protein is a major component of the typical surface structures, also known as spikes, present on all
 20 coronaviruses including IBV. A cDNA copy of this gene was isolated from IBV strain M41, a strain belonging to the Massachusetts serotype, and placed behind a promoter element derived from the long-terminal repeat sequence (LTR) of Rous Sarcoma Virus (RSV). The gene including the promoter was then transferred to the unique BglII restriction site in pMD07, the same as used previously for the insertion of the β -galactosidase expression cassette, and recombined into the viral genome of HVT. Recombinant progeny
 25 of the virus was screened for the expression of the spike gene and positive candidates were isolated and cloned by one or more platings at limiting dilution. Homogenous stocks of the recombinant IB/HVT virus were established and used for subsequent in vivo and in vitro characterization.

1. Isolation of the spike gene from IBV strain M41

30 Virus from IBV strain M41 was grown in 10 day-old embryonated eggs, by inoculating the allantoic cavity with 10^4 median egg infectious dose per egg. After 24 hours incubation at 37°C eggs were chilled overnight at 4°C . Allantoic fluid was harvested taking care to keep it cool on ice. Red blood cells and debris were removed by centrifugation at 4°C and $6000 \times g$ for 30'. Virus was pelleted from the supernatant at
 35 $54,000 \times g$ in a Beckmann Type 19 rotor for 4 hours at 4°C . The pellet was resuspended in cold TNE (10 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, pH 7.5) by repeated passage through a syringe needle and layered onto a 32 ml linear gradient of 20-60% sucrose in TNE. After overnight centrifugation at 4°C in a SW28 rotor at 24,000 rpm, virus band was collected through the side wall puncturing the tube with a syringe. After dilution with 2 volumes TNE, virus was pelleted in a SW28 rotor at 18,000 rpm for 90' at 4°C .
 40 Material was resuspended in a small volume of TNE and sodium dodecyl- sulphate was added to a final concentration of 0.5%. Preparation was digested with proteinase K (Boehringer) at $200 \mu\text{g/ml}$ for 2 hours at 37°C and extracted twice with a 1:1 mixture of phenol/chloroform. Viral RNA in the aqueous phase was precipitated with 2 volumes of ethanol in the presence of 0.1 M sodium acetate pH 6.0 at -20°C . After centrifugation and rinsing the tube with ethanol, the pellet was dried under vacuum and dissolved in sterile
 45 water to give a RNA concentration of 0.5 mg/ml. Preparation contained >90% of IBV genomic RNA as checked by agarose gel electrophoresis and was stored at -20°C . First strand cDNA synthesis was primed with oligo (dT)₁₂₋₁₈ in the presence of AMV reverse transcriptase using $5 \mu\text{g}$ of viral RNA in a $75 \mu\text{l}$ reaction volume. After incubating 30' at 44°C , DNA/RNA hybrids were denatured by heating 3' at 100°C followed by synthesis of the second strand in the presence of the large fragment from E. coli DNA
 50 polymerase I incubating the reaction for 2 hours at 20°C . cDNA was precipitated with ethanol and digested with 10 units of S_1 -nuclease in a $200 \mu\text{l}$ reaction volume for 30' at 37°C . Reaction products were layered onto 3.2 ml of a 5-20% sucrose gradient in 10 mM Tris-HCl, 5 mM EDTA, 500 mM NaCl, pH 7.5 and centrifuged in a SW65 rotor at 30,000 rpm for 16 hours at 15°C . Material sedimenting with a size between 500 and 5000 basepairs was collected, ethanol precipitated and dissolved in $20 \mu\text{l}$ of 0.1 SSC (15 mM
 55 NaCl, 1.5 mM sodium citrate). Ends of the double stranded cDNA were extended with 10 to 15 dG residues by a 2' incubation at 37°C with 15 units terminal transferase (Gibco-BRL) in a $30 \mu\text{l}$ reaction volume according to the conditions recommended by the enzyme supplier. Reaction was stopped with 5 mM EDTA. Ten nanograms of tailed cDNA were heated for 2' at 65°C with a 25-molar excess of the

phosphorylated synthetic oligomer 5'-dAATTCccccccccccc-3' in a final volume of 10 µl TEN and annealed together by overnight incubation at 50 °C. Ligation with 10 µg of EcoRI digested λgt10 DNA (Huynh et al., 1985) was in 20 µl of 30 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 10 mM DTT, 0.1 mM ATP, adding 1 unit of T4 DNA ligase and incubating overnight at 4 °C. DNA was added to *in vitro* packaging reaction mixture (Promega) and a cDNA library from IBV strain M41 was established by selecting for recombinant phages after plating on an hflA strain of E. coli.

The library was screened for cDNA clones encoding fragments of the spike protein by plating one to two hundred pfu in a petri dish on a lawn of E. coli. Duplicate filters of nitrocellulose were prepared (Benton and Davis, 1978) and incubated overnight at 42 °C with ³²P-labelled synthetic oligomers in a hybridization solution containing 10 mM Tris-HCl, pH 7.5, 1 M NaCl, 0.1% SDS and 4 x Denhardt's solution (Maniatis et al., 1982).

The three synthetic oligomers used as probes in these hybridizations contained the following nucleotide sequence structure:

I. 5'-dTtaggtggtctgaaggcactttggtagtagta-3'

II. 5'-dTACCTACTAATTTACCACCAGAACTACAACTGCTG-3'

III. 5'-dTGGATCATTAAACAGACTTTTtaggtctgtattggtt-3'

Recombinant phages giving a signal with one or preferentially two of these probes were selected and plaque purified by standard procedures (Maniatis et al., 1982). cDNA fragments from λ phage recombinants were flanked by EcoRI restriction sites and transferred as such into the EcoRI site from plasmid cloning vector pGEM3Z (Promega).

Restriction analysis and partial sequencing on two candidates showed that one encoded the complete S₁ and the other encoded the S₂ moiety of the spike gene. The sequence of these two DNA fragments partially overlapped with each other in particular with respect to the unique MluI-restriction site near the S₁/S₂ junction. This site was then used to assemble the two fragments mentioned above and resulted in a plasmid construction with a 3,7 kb BamHI insert, carrying the complete gene encoding the precursor for the protein peplomer from IBV strain M41.

2. Construction of the HVT recombination plasmid pIB18 encoding the spike gene from M41 controlled by a LTR promoter

A strong promoter which could direct the expression of foreign genes after their insertion into the genome of the HVT virus was selected from the LTR sequence of RSV. The promoter has been mapped on a 580 bp NdeI/HindIII restriction fragment from pRSVcat (Gorman et al., 1982) and was inserted between the HindIII and PstI sites of pGEM3Z (Promega) by means of double stranded synthetic linkers on both sides of the fragment. The connection between the HindIII site from the vector pGEM3Z and the NdeI site of the RSV fragment carrying the LTR-promotor was made with a 30 bp linker containing cohesive ends compatible with HindIII on one and NdeI on the other site. However, after ligation both restriction sites are not restored due to deliberate modifications in the outer nucleotides of the six basepair recognition sequence. In addition to the removal of these two sites, a new restriction site (BamHI) present within the linker itself was created at the corresponding position. A second 20 bp linker was synthesized which connected the HindIII site from the LTR fragment to the PstI site from pGEM3Z, in this case without destruction of the recognition sequence on either of the ends and adding the three convenient unique restriction sites BglII, XhoI and EcoRV, to those already present in the polylinker of pGEM3Z, e.g. PstI, SalI, XhoI and BamHI. The resulting derivative of pGEM3Z, designated pVEC01, therefore contains a 650 bp restriction fragment carrying the LTR promoter sequence immediately followed by seven restriction sites available for the insertion of foreign genes. The 650 bp fragment is flanked on either end by a BamHI restriction site and has been transferred as such to the unique BglII site present in the 1,2 kb HVT insert from pMD07. The cohesive ends generated by these two restriction enzymes are compatible but ligation does not restore either of the original recognition sequences for BglII or BamHI. One of the resulting constructs, carrying the LTR in the orientation towards the TR_s, was designated pVEC04 and checked by restriction mapping (Figure 4). The structure of this universal HVT recombination vector allows the insertion of foreign genes immediately downstream of the LTR promoter and subsequent integration of the complete expression cassette into the HVT genome by *in vivo* recombination. The positions of the different restriction sites downstream of the LTR in particular those for the enzymes BglII, XhoI and EcoRV are designed in such a way that even multiple gene insertion can be envisaged. A first application for this vector has been the construction of a recombinant HVT virus expressing the spike gene from IBV strain M41, the isolation of which has been described in the previous paragraph. A 3,7 kb BamHI restriction fragment carrying the spike gene from M41, was inserted into the unique BglII site of pVEC04 downstream of the LTR promoter. Again

this manipulation does not restore either of the restriction sites after ligation. One of the candidates having the gene inserted in the correct orientation relative to the LTR promotor, was analyzed by restriction mapping confirming the expected structure as presented in Figure 5. This plasmid was designated pIB18 and used subsequently in the co-transfection of chicken embryo fibroblasts (CEF).

5

3. Genomic insertion of the spike gene from IBV into HVT and expression of the peplomer protein

Linearized DNA from pIB18 was transfected together with total DNA from HVT infected chicken cells according to the method described in example 1 for the construction of β -galactosidase recombinants.

10 Detection of HVT recombinants expressing the spike protein was done by immunofluorescence staining using mono- or polyvalent sera against IBV. Primary cultures after the transfection were passed once on fresh CEF, harvested and sonicated as described before in example 1. After titration of the cell free lysates, microtitre plates with CEF were infected at limiting dilution using less than one pfu per well and incubated until CPE was detected. Cell suspensions from each of the wells separately were split over duplicate
15 microtitre plates together with fresh CEF and reincubated for two days. One of the plates was then fixed, stained with IBV specific sera and inspected for immuno-fluorescence under the microscope scoring those wells which contained a majority of IBV-positive staining HVT plaques.

Viable infected cells were recovered from the corresponding wells of the duplicated microtitre plate and amplified by one or two passages on fresh CEF. This cloning procedure based on limiting dilution was
20 repeated a number of times and resulted in several independent isolates of the recombinant HVT virus which all stained positively in the IBV specific immunofluorescence assay on infected cell cultures.

Example 5

25 1. Isolation of genes encoding the fusion (F) and hemagglutinin (HN) protein from Newcastle Disease Virus (NDV)

Virus from the NDV vaccine strain Clone 30 (Intervet International, Holland) was grown on embryonated eggs for 30 hours and allantoic fluid harvested after overnight incubation at +4 °C. Virus was purified over
30 a single sucrose gradient and genomic RNA was extracted by proteinase k digestion in the presence of SDS.

First strand cDNA synthesis was performed with reverse transcriptase using a random 10-base oligomer at 20 µg/ml to prime the reaction.

Second strand synthesis, S1-treatment and following steps including insertion into the λ gt10 vector were
35 done as described previously under section 1 of example 4.

Screening of the library for F-gene specific sequences was done by plaque hybridization with the ³²P-labelled oligonucleotides.

I 5'GGCAGGCCTCTTGCGGCTGCAGGGATTGTGGTAACAGG 3'

II 5'GCAAAAGGCGCAACAGAAGACCTTGTTGTGGCTTGGC 3'

40 recognizing 5' and 3' extremities of the coding region, respectively. Identification of HN-gene sequences was done with the oligonucleotides.

III 5'GAAAGAGAGGCGAAGAATACATGGCGCTTGGTATTCCGG 3'

IV 5'GAAATATCTAATACTCTCTTCGGGGAATTCAGGATCGT 3'

The sequence of these probes was designed by comparing published data on NDV-strains Australia-Victoria
45 (McGinnes et al., 1986), Italien (Espion, et al., 1987 and Wemers, et al., 1987), Beaudette (Chambers et al., 1986 and Millar et al., 1986) and D26 (Sato et al., 1987).

Positive candidates giving a signal with at least two of the probes were isolated and characterized by restriction mapping. From this series, two were selected covering respectively the F and HN from NDV strain-Clone 30.

50 The DNA inserts were transferred to the plasmid vector pGEM4Z and manipulated with the exonuclease Bal 31 to remove excessive or overlapping sequences up- or downstream of the actual coding region of the F- and HN-gene.

This resulted in the plasmids pNDV01 and pNDV03 containing the complete gene coding for F respectively HN flanked by Bam HI restriction sites.

55

2. Genomic insertion of F- and HN-gene from NDV into HVT.

Bam. HI fragment of plasmid pNDV01 and pNDV03, containing the genes encoding F and HN respectively, were inserted into the Bgl II site of the HVT recombination vector pVEC04 resulting in pNDV04 and pNDV05.

Correct orientation of inserted genes relative to the LTR promotor was verified by restriction analysis based on the physical map of these construct shown in Fig. 6.

DNA from these plasmids is co-transfected together with DNA from HVT infected cells into CEF as described in section 2 of example 1.

After amplification of transfected cultures, cel-free lysates were established and plated onto microtiter dishes.

Detection of HVT recombinants expressing the F or HN protein was done by immunofluorescence staining using polyvalent NDV sera or monoclonal antibodies against specific NDV antigens.

Enrichment of HVT recombinant virus was done by limiting dilution as described in section 3 of example 4.

Establishment of a homogenous recombinant virus preparation was done by single plaque isolation and testing for expression of F respectively HN in infected CEF by immunofluorescence staining.

Legends to the figures

20 Figure 1

Restriction enzyme map of a DNA fragment essentially corresponding to the Us region of the HVT genome. The relative position of the insertion-region consisting of four open reading frames and non-coding sequences in between is indicated.

25

Figure 2

A) Restriction map of pMD07gal. This plasmid has been derived from pMD07 by inserting the β -galactosidase gene into the unique BglII restriction site present in the 1.2 kb XhoI fragment of the HVT genome.

30

B) Restriction map of pMD12gal. This plasmid has been derived from pMD12 by inserting the β -galactosidase gene into the unique BglII restriction site present in the 3.5 kb XhoI fragment of the HVT genome.

35 Figure 3

A) Restriction map of pMD40. A 1117 bp SpeI fragment present in pMD12 was replaced by a synthetic oligonucleotide containing a Sall site.

40

B) Restriction map of pMD44. Derived from pMD40 by insertion of a 4.0 ks β -galactosidase marker gene flanked by Sall sites into the Sall site of pMD40.

Figure 4

Restriction enzyme map of pVEC04 showing the LTR-promotor inserted into the unique BglII site of the 1,2 kb XhoI HVT fragment from pMD07.

45

Figure 5

Restriction enzyme map of pIB18 showing the 3,7 kb BamHI fragment carrying the spike gene from IBV strain M41 inserted into the BglII site of pVEC04 downstream of the LTR promotor.

50

Figure 6

A) Restriction map of pNDV04. Plasmid contains NDV-F gene flanked by BamHI sites inserted into Bgl II site of pVEC04 (see Fig. 4).

55

B) Restriction map of pNDV05. Plasmid contains NDV-HN gene flanked by BamHI sites inserted into Bgl II site of pVEC04 (see Fig. 4).

References

1. Benton, W.D. and Davis, R.W. (1978), Science, 196, 180.
2. Chambers et al. (1986), J. Gen. 67, 2685.
- 5 3. Espion et al. (1987), Arch. Virol. 95, 79.
4. Gorman, C. et al. (1982), Proc. Natl. Acad. Sci. USA, 79, 6777.
5. Graham, F. and v.d. Eb, A. (1973), Virology, 52, 456.
6. Henikoff, S. (1984), Gene, 28, 351.
7. Huynh, T.V., et al. (1985) in "DNA cloning, Vol. I", ed. D. Glover, pag. 49.
- 10 8. Igarashi, T., et al. (1987), Virology, 157, 351.
9. Maniatis, T., et al. (1982) in "Molecular cloning", Cold Spring Harbor laboratory.
10. McGinnes et al. (1986), Virus Res. 5, 343.
11. Millar et al. (1986), J. Gen. Virol. 67, 1917.
12. Sanger, I., et al. (1977), Proc. Natl. Acad. Sci. USA, 74, 5463.
- 15 13. Sato et al. (1987), Virus Res. 7, 241.
14. Wemers et al. (1987), Arch. Virol. 97, 101.

SEQUENCE LISTING

20

25

30

35

40

45

50

55

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4527 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Herpesvirus of turkey
- (B) STRAIN: PB-THV1

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..81
- (D) OTHER INFORMATION: /label= end_of_ORF1

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 316..945
- (D) OTHER INFORMATION: /label= ORF2

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: complement (1084..2124)
- (D) OTHER INFORMATION: /label= ORF3

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: complement (2322..3170)
- (D) OTHER INFORMATION: /label= ORF4

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 3320..4504
- (D) OTHER INFORMATION: /label= ORF5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

	AACAGTTATA	TACGCGCATC	GGGCCACGTT	CCGCCTTCGA	GGGCACCTCC	GACAGATACG	60
5	AATTTAAAGA	TGGATGAATA	ATTAAATTGG	AAAGAGTAAC	TATATTAATC	GAGCGTCATG	120
	ACGGCGTCCC	GTGAAAATGA	GAATTTTCTA	CTCGAAACAC	CGTGACATTT	GACAGACCTG	180
	GACTTGTTAT	TCTGATATAT	AGTGGGTGTG	TCTGACCGGC	AACATACATA	ATGTGCATGC	240
10	GAAACCACTT	TTTCAGTGTA	CGCTGACATT	GTGCAACACG	GAGGGGTAGC	ATCTACATAC	300
	AATATATGTT	GATTAATGAT	TGGAGAAAAA	ACTATGCAGC	TCGCCGATCA	TATGGCTAAC	360
	TCGCCTTCGC	CTATATGGCG	GACCCCGCGG	GAAAAATCGA	CGTACCATCT	GATTTACAAC	420
15	ACCAGTAATG	AACATGTCGC	ATCCCTGCCC	AGATCTGTGC	GCCCATTTGGC	GCGTATCGTT	480
	GTGAATGCCG	CCGAAACACT	TCAGGTCGGT	ATGAGAGCCG	GGAGGCCGCC	ATCAGCAGGA	540
	GTTTGCGCAG	AGGTGTTTGA	TAGAATGATG	ACAGCCTTCC	GTGACTACGA	GCCTACTGCG	600
20	ACATTTAATG	CTGCAGATCC	CATTAGAAAA	ATGGTCGAGA	CAGTTCTACA	GAATAATGAA	660
	GAGCCTCCGC	GGACGCATGC	TGAAATGGGT	AATCGCCTTA	TGAACATTAT	GTACTGGTGT	720
	TGCTTGGGAC	ACGCAGGACA	ATGCTCGATC	TGGCAGTTGT	ACGAGACGAA	TCAGGCCATT	780
25	TTAAGTTTAT	TAGATGAAGT	GGTTATCGGC	ACAACAAATC	CCTTTTGAC	CCTCGAGCAA	840
	TACTGGAAGC	CATTATGCAC	CGCAATCGCC	AACAAGGGGA	CCTCATCGCT	TGTTGAGGAT	900
	GCCAAAGTGG	CCGAGTACCT	GGTTAGCATG	CGCAAATTGA	TATAACACAG	GCACGCTCTG	960
30	ATGTTACAGA	CCACAATACC	GCATACATTT	ATTGTAAGGT	TGTTAATAAA	GGTTTATTCT	1020
	ATGTAAGACT	ACAATACTTT	TGACATTGCT	TGTATACATA	TTAAATACTT	TCTCAAGTTC	1080
	CTATTACATA	AAATGGGATC	TATCATTACA	TTCGTTAAGA	GTCTGGATAA	TTTTACTGTT	1140
35	TGCCAGCTTC	GATCTTGGA	CGTACTGTGG	ATAGTGCCTT	ACTTGGAATC	GTGAAAATTT	1200
	GAAGCGTTCA	TTATTTGGAT	ATCTTCCGGT	TGTCCCATAT	CCCGCCCTGG	TACCGCTCGG	1260
	ATACCTTGCC	CGTATGGATT	CGTATTGACA	GTGCGCAAT	TGGGGACCAA	CAACGCGTGG	1320
40	GTCCCACTC	ATTCGGAAAT	TTTCCGATGA	TTCTGAATAT	TTATTGCCGC	TCGTTACGAG	1380
	TTGTTGGACA	TATCTGTAAT	ACAGTTCTTC	TTCTGAAGGA	TCGCTGCACA	TTTGATCTAT	1440
	ACATTGGCCA	GGATGTTCAA	GTCTCAGATG	TTGCATTCTG	GCACAGCACA	ACTTTATGGC	1500

45

50

55

	ATTTCCGACG	TAATCGTCCG	GCAGCCCTGG	GGGAGTTCTA	TATTCGCATA	TTGGGATGGT	1560
	AAGGACAATA	GCAGATCTCG	CAACCTCCAG	GGAGGCTATA	ATAACGTTTT	TAAAGGATGG	1620
5	ACTTCTCATA	AAAATCTGTC	GCAAATTACA	CTGAGAATAT	CCTTTACTAG	CGCCGATTGA	1680
	GAGCATCGTC	GTCCAATTTT	CTAAATGGAA	AGAAAACAAG	GCGGGCAAGA	GTGTTCCAAA	1740
	CATTTTCATT	TTCGACGAAT	CTCTCAAATC	CCATGGCGTG	CAATTGATTG	CAAAATTGGC	1800
10	ACTTCCGTTC	ACGTTTGTAT	CTCCAACTC	TAAGATACTT	TTAATTGAAA	AACTACGTTC	1860
	TAGTGTGGAA	AGAAACCTAT	AGGCAGACCA	TAGAACTATT	TGACACCACA	TATCTTTTTG	1920
	TATGTCAAAC	TGACCATGAT	CGCATGTTGC	TGAATGCACT	AGGGCAATTC	GCTCGCGCGA	1980
15	CTCCATACAT	TGAATAATTC	CACACGTCAG	CTCATCTGTT	AGCAAGGTCC	AGTAGTTGAA	2040
	GTCATTTATT	TTCCCCGCG	GCTGGCCAAA	TCTACCTCTG	GGAATATCCA	AGTTGTGCGA	2100
	TATGATCGCA	CCGGCTCTGG	TCATGGTGAA	GGAAGTTGTA	GCATAAAGAC	GCAGGTATCA	2160
20	TAGGGGTAAT	ATTTTTTATT	CACTCACATG	CAAAAAGTAA	CGCATATTAG	CACCATGTAT	2220
	GGGCCATCAA	TTGACATTTG	CGTAGCACTA	CATCACGATT	ATGTACAACA	TAATGGGACA	2280
	ACAAATGGCA	AGTAGATGCA	ATTTCCCTCAC	ACTAGTTGGG	TTTATCTACT	ATTGAATTTT	2340
25	CCCCATCTG	TGATACACTT	GGGAGCCTCT	ACAAGCATAT	TGCCATCATG	TACGTTTTTA	2400
	TCTACTGTCT	TAACGCCCAT	GGGAACGGAG	GCGTCGTCGT	CATGTATTGG	ACGGCAACAT	2460
	AGGCAGCAAC	ACAAATTGCG	TTTAGGTGGG	GTGCATGTGG	ACTCGATACC	AAGACCCTGC	2520
	AGCTGGGGAA	CGTCTGGTGG	AGAGCCGATA	ATTTGATATA	CGCACGCCAT	ATTACTATCG	2580
30	TTGAAGTACG	CCTTATCTTC	TATGTTTTCA	AATTTAGGTT	CCCAAGTGGA	CGTGAGAAGT	2640
	GTTTGTATCT	CACATGGAAG	GGCCCAAGGC	ATTCCAGCCC	AGGTGCCTGG	TACTTTAATG	2700
	GCAAACAAAC	GTTTTGGTAG	AGGTATTGAT	TCTATTGCAG	TTCTGCAGAT	ATCTGCAGCT	2760
35	CCGAGTATCC	ACAGGCTATA	CGATACGTTA	TCGGAGGCCT	CCGATTCTAG	CATTACATAG	2820
	CCGGTCAGTA	GATCCTGCCA	TTCGGTAGCG	CAACCGGCTA	CATCTTCAAA	CAGTCTCACA	2880
	ATAAATGCAT	CTCTCGTTCC	TGCCAATCCG	GAACCGGGCA	TACCACTCCC	ACCTGCCGAT	2940
40	TTAATTCTCA	CAATTGGGCG	ATGCCGGCGG	GGCAAAACGA	ATGTGGATTT	GGCAAACCGA	3000
	CACAGGTCTG	CTGTACGGAC	TAATATGGGC	ACACCCACAT	CATTCTTCAG	ATGCTCCATG	3060
	CATTGTTCTA	TGAGAAAGAT	CCATAGGGTG	GAGGCAGCGT	CACGAGATCG	CCCAGGCAAT	3120
45	CGATCGCATT	CGTCTAGTAA	AGTGACGAGA	GTTATCATGC	ACACACCCAT	GCCCACGCGT	3180

50

55

EP 0 431 668 B1

TCCGAATAAC TGGAGCTGTG GAAGATCGGA AACGTCTTTT TGA CTG CCGG TCTCGTACTA 3240
 CTTTCGCACA GGTGTATACC CGGACGCGTA CTATATATTT TATATCATTC AACGTCCCGA 3300
 5 AATTACATAC GTGGCGGCGA TGGAAGTAGA TGTTGAGTCT TCGAAAGTAA GTGCCCTCGAA 3360
 TATGGGTATT GTCTGTGAAA ATATCGAAAG CGGTACGACG GTTGCAGAAC CGTCGATGTC 3420
 GCCAGATACT AGTAACAATA GCTTCGATAA CGAAGACTTC CGTGGGCCTG AATACGATGT 3480
 10 GGAGATAAAT ACCAGAAAAT CTGCTAATCT TGATCGTATG GAATCTTCGT GCCGTGAACA 3540
 ACGAGCGGCG TCGGAACTTC GAAAGTGTTT GTGTCCTACG TCTGCCGTGC GCATGCAATA 3600
 CAGTATTCTT TCATCTCTCG CTCCGGGTTC AGAGGGTCAT GTATATATAT GTACTAGATA 3660
 15 CGGGGACGCG GACCAAAAAA AATGCATAGT GAAGGCAGTC GTTGGAGGAA AGAATCCCGG 3720
 GAGGGAAGTG GATATTTTAA AAACCATCTC ACATAAATCA ATTATAAAAT TAATCCATGC 3780
 CTATAAATGG AAAAATGTTG TGTGTATGGC AATGCGTGTA TATCGTTATG ATCTTTTCAC 3840
 20 ATATATTGAC GGAGTCGGCC CTATGCCCCCT TCAACAGATG ATCTATATTC AACGTGGACT 3900
 ACTAGAGGCG CTAGCATACA TACATGAAAG GGGCATCATT CACCGAGACG TAAAGACGGA 3960
 GAATATATTC TTGGATAATC ACGAAAATGC AGTTTTGGGT GACTTCGGTG CTGCATGTCA 4020
 25 ACTAGGAGAT TGTATAGATA CGCCCCAATG TTACGGTTGG AGCGGAACTG TGGAAACAAA 4080
 TTCGCCGGAA TTATCTGCAC TTGATCCGTA TTGCACAAAA ACAGATATTT GGAGTGCCGG 4140
 ATTGGTTCTA TATGAGATGG CAATTAAAAA TGTACCATTG TTTAGTAAGC AGGTGAAAAG 4200
 TTCGGGATCT CAGCTGAGAT CCATAATACG GTGCATGCAA GTGCATGAAC TGGAGTTTCC 4260
 30 CCGCAACGAT TCTACCAACC TCTGTAAACA TTTCAAACAA TATGCGGTTC GTGTACGACC 4320
 GCCTTATACC ATTCCTCGAG TTATAAGAAA TGGGGGGATG CCAATGGATG TTGAATATGT 4380
 CATTTCTAAA ATGCTTACGT TTGACCAGGA GTTCAGACCT TCTGCTAAGG AAATATTGAA 4440
 35 TATGCCCCTA TTTACTAAGG CGCCGATTAA CCTGCTTAAT ATCACACCCT CTGACAGTGT 4500
 CTAACGGTAT ACAGGCGGGA GCGGGTA 4527

40

45

50

55

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 209 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE: ORF-2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

15  Met Ile Gly Glu Lys Thr Met Gln Leu Ala Asp His Met Ala Asn Ser
    1           5           10           15
    Pro Ser Pro Ile Trp Arg Thr Pro Arg Glu Lys Ser Thr Tyr His Leu
          20           25           30
20  Ile Tyr Asn Thr Ser Asn Glu His Val Ala Ser Leu Pro Arg Ser Val
    35           40           45
    Arg Pro Leu Ala Arg Ile Val Val Asn Ala Ala Glu Thr Leu Gln Val
    50           55           60
25  Gly Met Arg Ala Gly Arg Pro Pro Ser Ala Gly Val Trp Arg Glu Val
    65           70           75           80
    Phe Asp Arg Met Met Thr Ala Phe Arg Asp Tyr Glu Pro Thr Ala Thr
          85           90           95
30  Phe Asn Ala Ala Asp Pro Ile Arg Lys Met Val Glu Thr Val Leu Gln
    100          105          110
    Asn Asn Glu Glu Pro Pro Arg Thr His Ala Glu Met Gly Asn Arg Leu
    115          120          125
35  Met Asn Ile Met Tyr Trp Cys Cys Leu Gly His Ala Gly Gln Cys Ser
    130          135          140
    Ile Trp Gln Leu Tyr Glu Thr Asn Gln Ala Ile Leu Ser Leu Leu Asp
    145          150          155          160
    Glu Val Val Ile Gly Thr Thr Asn Pro Phe Cys Thr Leu Glu Gln Tyr
          165          170          175
45  Trp Lys Pro Leu Cys Thr Ala Ile Ala Asn Lys Gly Thr Ser Ser Leu
    180          185          190
    Val Glu Asp Ala Lys Val Ala Glu Tyr Leu Val Ser Met Arg Lys Leu
    195          200          205
50  Ile
    209

```

55

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 346 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE: ORF-3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

5 Met Thr Arg Ala Gly Ala Ile Ile Phe Asp Asn Leu Asp Ile Pro Arg
 1 5 10 15
 10 Gly Arg Phe Gly Gln Pro Arg Gly Lys Ile Asn Asp Phe Asn Tyr Trp
 20 25 30
 15 Thr Leu Leu Thr Asp Glu Leu Thr Cys Gly Ile Ile Gln Cys Met Glu
 35 40 45
 20 Ser Arg Glu Arg Ile Ala Leu Val His Ser Ala Thr Cys Asp His Gly
 50 55 60
 25 Gln Phe Asp Ile Gln Lys Asp Met Trp Cys Gln Ile Val Leu Trp Ser
 65 70 75 80
 30 Ala Tyr Arg Phe Leu Ser Thr Leu Glu Arg Ser Phe Ser Ile Lys Ser
 85 90 95
 35 Ile Leu Glu Phe Gly Asp Thr Asn Val Asn Gly Ser Ala Asn Phe Ala
 100 105 110
 40 Ile Asn Cys Thr Pro Trp Asp Leu Arg Asp Ser Ser Lys Met Lys Met
 115 120 125
 45 Phe Gly Thr Leu Leu Pro Ala Leu Phe Ser Phe His Leu Glu Asn Trp
 130 135 140
 50 Thr Thr Met Leu Ser Ile Gly Ala Ser Lys Gly Tyr Ser Gln Cys Asn
 145 150 155 160
 55 Leu Arg Gln Ile Phe Met Arg Ser Pro Ser Phe Lys Asn Val Ile Ile
 165 170 175
 60 Ala Ser Leu Glu Val Ala Arg Ser Ala Ile Val Leu Thr Ile Pro Ile
 180 185 190
 65 Cys Glu Tyr Arg Thr Pro Pro Gly Leu Pro Asp Asp Tyr Val Gly Asn
 195 200 205

Ala Ile Lys Leu Cys Cys Ala Arg Met Gln His Leu Arg Leu Glu His
 210 215 220
 5 Pro Gly Gln Cys Ile Asp Gln Met Cys Ser Asp Pro Ser Glu Glu Glu
 225 230 235 240
 Leu Tyr Tyr Arg Tyr Val Gln Gln Leu Val Thr Ser Gly Asn Lys Tyr
 245 250 255
 10 Ser Glu Ser Ser Glu Asn Phe Arg Met Ser Val Asp Pro Arg Val Val
 260 265 270
 Gly Pro Gln Leu Arg Asp Cys Gln Tyr Glu Ser Ile Arg Ala Arg Tyr
 275 280 285
 15 Pro Ser Gly Thr Arg Ala Gly Tyr Gly Thr Thr Gly Arg Tyr Pro Asn
 290 295 300
 Asn Glu Arg Phe Lys Phe Ser Arg Phe Gln Val Arg His Tyr Pro Gln
 305 310 315 320
 20 Tyr Val Pro Arg Ser Lys Leu Ala Asn Ser Lys Ile Ile Gln Thr Leu
 325 330 335
 Asn Glu Cys Asn Asp Arg Ser His Phe Met
 340 345

25

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

30

- (A) LENGTH: 282 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

35

- (ii) MOLECULE TYPE: protein
 (ix) FEATURE: ORF-4
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

40

Met Gly Val Cys Met Ile Thr Leu Val Thr Leu Leu Asp Glu Cys Asp
 1 5 10 15
 Arg Leu Pro Gly Arg Ser Arg Asp Ala Ala Ser Thr Leu Trp Ile Phe
 20 25 30
 45 Leu Ile Glu Gln Cys Met Glu His Leu Lys Asn Asp Val Gly Val Pro
 35 40 45

50

55

Ile Leu Val Arg Thr Ala Asp Leu Cys Arg Phe Ala Lys Ser Thr Phe
 50 55 60
 5 Val Leu Pro Arg Arg His Arg Pro Ile Val Arg Ile Lys Ser Ala Gly
 65 70 75 80
 Gly Ser Gly Met Pro Gly Ser Gly Leu Ala Gly Thr Arg Asp Ala Phe
 85 90 95
 10 Ile Val Arg Leu Phe Glu Asp Val Ala Gly Cys Ala Thr Glu Trp Gln
 100 105 110
 Asp Leu Leu Thr Gly Tyr Val Met Leu Glu Ser Glu Ala Ser Asp Asn
 115 120 125
 15 Val Ser Tyr Ser Leu Trp Ile Leu Gly Ala Ala Asp Ile Cys Arg Thr
 130 135 140
 Ala Ile Glu Ser Ile Pro Leu Pro Lys Arg Leu Phe Ala Ile Lys Val
 145 150 155 160
 20 Pro Gly Thr Trp Ala Gly Met Pro Trp Ala Leu Pro Cys Glu Ile Gln
 165 170 175
 Thr Leu Leu Thr Ser Thr Trp Glu Pro Lys Phe Glu Asn Ile Glu Asp
 180 185 190
 25 Lys Ala Tyr Phe Asn Asp Ser Asn Met Ala Cys Val Tyr Gln Ile Ile
 195 200 205
 Gly Ser Pro Pro Asp Val Pro Gln Leu Gln Gly Leu Gly Ile Glu Ser
 210 215 220
 30 Thr Cys Thr Pro Pro Lys Arg Asn Leu Cys Cys Cys Leu Cys Cys Arg
 225 230 235 240
 35 Pro Ile His Asp Asp Asp Ala Ser Val Pro Met Gly Val Lys Thr Val
 245 250 255
 Asp Lys Asn Val His Asp Gly Asn Met Leu Val Glu Ala Pro Lys Cys
 260 265 270
 40 Ile Thr Asp Arg Gly Lys Phe Asn Ser Arg
 275 280

45

50

55

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 394 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE: ORF-5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Glu Val Asp Val Glu Ser Ser Lys Val Ser Ala Ser Asn Met Gly
 1 5 10 15
 Ile Val Cys Glu Asn Ile Glu Ser Gly Thr Thr Val Ala Glu Pro Ser
 20 20 25 30
 Met Ser Pro Asp Thr Ser Asn Asn Ser Phe Asp Asn Glu Asp Phe Arg
 35 40 45
 Gly Pro Glu Tyr Asp Val Glu Ile Asn Thr Arg Lys Ser Ala Asn Leu
 25 50 55 60
 Asp Arg Met Glu Ser Ser Cys Arg Glu Gln Arg Ala Ala Cys Glu Leu
 65 70 75 80
 Arg Lys Cys Ser Cys Pro Thr Ser Ala Val Arg Met Gln Tyr Ser Ile
 30 85 90 95
 Leu Ser Ser Leu Ala Pro Gly Ser Glu Gly His Val Tyr Ile Cys Thr
 35 100 105 110
 Arg Tyr Gly Asp Ala Asp Gln Lys Lys Cys Ile Val Lys Ala Val Val
 115 120 125
 Gly Gly Lys Asn Pro Gly Arg Glu Val Asp Ile Leu Lys Thr Ile Ser
 40 130 135 140
 His Lys Ser Ile Ile Lys Leu Ile His Ala Tyr Lys Trp Lys Asn Val
 145 150 155 160
 Val Cys Met Ala Met Arg Val Tyr Arg Tyr Asp Leu Phe Thr Tyr Ile
 45 165 170 175
 Asp Gly Val Gly Pro Met Pro Leu Gln Gln Met Ile Tyr Ile Gln Arg
 180 185 190
 Gly Leu Leu Glu Ala Leu Ala Tyr Ile His Glu Arg Gly Ile Ile His
 50 195 200 205

Arg Asp Val Lys Thr Glu Asn Ile Phe Leu Asp Asn His Glu Asn Ala
 210 215 220
 Val Leu Gly Asp Phe Gly Ala Ala Cys Gln Leu Gly Asp Cys Ile Asp
 5 225 230 235 240
 Thr Pro Gln Cys Tyr Gly Trp Ser Gly Thr Val Glu Thr Asn Ser Pro
 245 250 255
 10 Glu Leu Ser Ala Leu Asp Pro Tyr Cys Thr Lys Thr Asp Ile Trp Ser
 260 265 270
 Ala Gly Leu Val Leu Tyr Glu Met Ala Ile Lys Asn Val Pro Leu Phe
 275 280 285
 15 Ser Lys Gln Val Lys Ser Ser Gly Ser Gln Leu Arg Ser Ile Ile Arg
 290 295 300
 Cys Met Gln Val His Glu Leu Glu Phe Pro Arg Asn Asp Ser Thr Asn
 305 310 315 320
 20 Leu Cys Lys His Phe Lys Gln Tyr Ala Val Arg Val Arg Pro Pro Tyr
 325 330 335
 Thr Ile Pro Arg Val Ile Arg Asn Gly Gly Met Pro Met Asp Val Glu
 25 340 345 350
 Tyr Val Ile Ser Lys Met Leu Thr Phe Asp Gln Glu Phe Arg Pro Ser
 355 360 365
 30 Ala Lys Glu Ile Leu Asn Met Pro Leu Phe Thr Lys Ala Pro Ile Asn
 370 375 380
 Leu Leu Asn Ile Thr Pro Ser Asp Ser Val
 385 390

35

Claims

Claims for the following Contracting States : BE, CH, DE, FR, GB, IT, LI, NL, SE

- 40 1. Recombinant Herpesvirus of Turkeys (HVT) characterized in that it contains a heterologous nucleic acid sequence, said nucleic acid sequence being introduced in an insertion-region of the HVT genome which corresponds with the genomic region from the end of ORF-1 up to and including ORF-5 located within a DNA fragment of the HVT genome having a restriction enzyme map defined by figure 1 or a variant of said genomic region.
- 45 2. Recombinant HVT, characterized in that it contains a heterologous nucleic acid sequence, said nucleic acid sequence being introduced in an insertion-region of the HVT-genome that corresponds with the DNA sequence between nucleotide positions 82 and 4505, defined by the DNA sequence shown in SEQ ID NO: 1 or a variant of said DNA sequence.
- 50 3. Recombinant HVT according to claims 1-2, characterized in that the insertion-region corresponds with ORF-2 or ORF-3.
- 55 4. Recombinant HVT according to claim 3, characterized in that the heterologous nucleic acid sequence is incorporated at the BglII restriction site present in ORF-2 or ORF-3.
5. Recombinant HVT according to claims 1-4, characterized in that at least a part of the HVT nucleic acid sequence within the insertion-region is deleted.

6. Recombinant HVT according to claims 1-5, characterized in that the heterologous nucleic acid sequence encodes a polypeptide and is under control of a promotor regulating the expression of said nucleic acid sequence in a cell infected with said recombinant HVT.
- 5 7. Recombinant HVT according to claims 1-6, characterized in that the heterologous nucleic acid sequence encodes a antigen of an avian pathogen.
8. Recombinant HVT according to claim 7, characterized in that the antigen is derived from the group comprising Marek's Disease Virus, Infectious Bronchitis Virus, Newcastle Disease Virus or Infectious Bursal Disease Virus.
- 10 9. Nucleic acid sequence comprising at least a gene heterologous to HVT, or part thereof, under control of a promoter, flanked by DNA sequences derived from the insertion region of the HVT genome as defined in claim 1.
- 15 10. Recombinant DNA molecule comprising a nucleic acid sequence according to claim 9.
11. Host cell transformed with a nucleic acid sequence according to claim 9 or, a recombinant DNA molecule according to claim 10.
- 20 12. Process for the preparation of a recombinant HVT according to claims 1-8, characterized in that an appropriate cell culture is co-transfected with HVT DNA and a recombinant DNA molecule according to claim 10.
- 25 13. Cell culture infected with a recombinant HVT according to claims 1-8.
14. Vaccine comprising a recombinant HVT according to claims 1-8.
15. Vaccine, pharmaceutical or diagnostic composition comprising a polypeptide expressed by a recombinant HVT according to claims 1-8.
- 30 16. Process for the preparation of a vaccine, characterized in that HVT containing material is collected from a cell culture according to claim 13 and processed into a vaccine.
- 35 17. Process for the preparation of a vaccine, pharmaceutical or diagnostic composition, characterized in that a polypeptide expressed by a recombinant HVT according to claims 1-8 is processed into a preparation with immunizing, therapeutic or diagnostic activity.
18. Antiserum comprising antibodies evoked by a recombinant HVT according to claims 1-8 and binding specifically thereto.
- 40

Claims for the following Contracting States : ES, GR

1. Process for the preparation of a recombinant Herpesvirus of Turkeys (HVT) characterized in that a heterologous nucleic acid sequence is introduced in an insertion-region of the HVT genome which corresponds with the genomic region from the end of ORF-1 up to and including ORF-5 located within a DNA fragment of the HVT genome having a restriction enzyme map defined by figure 1 or a variant of said genomic region.
- 45 2. Process according to claim 1, characterized in that the heterologous nucleic acid sequence, is introduced in an insertion-region of the HVT-genome that corresponds with the DNA sequence between nucleotide positions 82 and 4505, defined by the DNA sequence shown in SEQ ID NO: 1 or a variant of said DNA sequence.
- 50 3. Process according to claims 1-2, characterized in that the insertion-region corresponds with ORF-2 or ORF-3.
- 55

4. Process according to claim 3, characterized in that the heterologous nucleic acid sequence is incorporated at the Bg1II restriction site present in ORF-2 or ORF-3.
5. Process according to claims 1-4, characterized in that at least a part of the HVT nucleic acid sequence within the insertion-region is deleted.
6. Process according to claims 1-5, characterized in that the heterologous nucleic acid sequence encodes a polypeptide and is under control of a promotor regulating the expression of said nucleic acid sequence in a cell infected with said recombinant HVT.
7. Process according to claims 1-6, characterized in that the heterologous nucleic acid sequence encodes an antigen of an avian pathogen.
8. Process according to claim 7, characterized in that the antigen is derived from the group comprising Marek's Disease Virus, Infectious Bronchitis Virus, Newcastle Disease Virus or Infectious Bursal Disease Virus.
9. Process for the preparation of a nucleic acid sequence comprising linking a gene heterologous to HVT, or part thereof, under control of a promoter, to flanking DNA sequences derived from the insertion region of the HVT genome as defined in claim 1.
10. Process for the preparation of a recombinant DNA molecule comprising inserting a nucleic acid sequence prepared according to the process of claim 9 in a vector.
11. Process for the preparation of a transformed host cell comprising introducing into a host cell, a nucleic acid sequence prepared according to the process of claim 9 or, a recombinant DNA molecule prepared according to the process of claim 10.
12. Process for the preparation of a recombinant HVT, characterized in that an appropriate cell culture is co-transfected with HVT DNA and a recombinant DNA molecule comprising a gene heterologous to HVT, or part thereof, under control of a promoter, flanked by DNA sequences derived from the insertion- region of the HVT genome as defined in claim 1.
13. Process for the preparation of a cell culture infected with a recombinant HVT, characterized in that a recombinant HVT prepared according to the process of claims 1-8 or 12 is added to a suitable cell culture.
14. Process for the preparation of a vaccine, characterized in that a recombinant HVT prepared according to the process of claims 1-8 or 12 is mixed with a pharmaceutically acceptable carrier.
15. Process for the preparation of a vaccine, pharmaceutical or diagnostic composition, characterized in that a polypeptide expressed by a recombinant HVT prepared according to the process of claims 1-8 or 12 is processed into a preparation with immunizing, therapeutic or diagnostic activity.
16. Process for the preparation of antiserum comprising immunizing an animal with a recombinant HVT prepared according to the process of claims 1-8 or 12, eliciting antibodies binding specifically thereto, and collecting the antisera from the animal.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : BE, CH, DE, FR, GB, IT, LI, NL, SE

1. Rekombinantes Truthahnherpesvirus (HVT) dadurch gekennzeichnet, dass es eine heterologe Nukleinsäuresequenz enthält, besagte Nukleinsäuresequenz ist in eine Insertionsregion des HVT-Genoms eingeführt, die der genomischen Region vom Ende des ORF-1 bis zu und einschliesslich ORF-5 entspricht, die sich innerhalb eines DNA-Fragments des HVT-Genoms befinden, welches eine durch Figur 1 definierte Restriktionsenzymkarte hat oder eine Variante der genomischen Region.

2. Rekombinantes HVT, dadurch gekennzeichnet, dass es eine heterologe Nukleinsäuresequenz enthält, besagte Nukleinsäuresequenz ist in eine Insertionsregion des HVT-Genoms eingeführt, die der DNA-Sequenz zwischen den Nukleotidpositionen 82 und 4505 entspricht, die durch die in SEQ ID NO:1 gezeigte DNA-Sequenz oder eine Variante besagter DNA-Sequenz definiert ist.
3. Rekombinantes HVT gemäss Ansprüchen 1-2, dadurch gekennzeichnet, dass die Insertionsregion ORF-2 oder ORF-3 entspricht.
4. Rekombinantes HVT gemäss Anspruch 3, dadurch gekennzeichnet, dass die heterologe Nukleinsäuresequenz in die BglII-Schnittstelle eingebaut ist, die sich im ORF-2 oder ORF-3 befindet.
5. Rekombinantes HVT gemäss Ansprüchen 1-4, dadurch gekennzeichnet, dass mindestens ein Teil der HVT-Nukleinsäuresequenz innerhalb der Insertionsregion deletiert ist.
6. Rekombinantes HVT gemäss Ansprüchen 1-5, dadurch gekennzeichnet, dass die heterologe Nukleinsäuresequenz für ein Polypeptid codiert und unter Kontrolle eines Promotors steht, der die Expression besagter Nukleinsäuresequenz in einer Zelle, die mit besagtem rekombinanten HVT infiziert ist, reguliert.
7. Rekombinantes HVT gemäss Ansprüchen 1-6, dadurch gekennzeichnet, dass die heterologe Nukleinsäuresequenz für ein Antigen eines aviären Krankheitserregers codiert.
8. Rekombinantes HVT gemäss Anspruch 7, dadurch gekennzeichnet, dass das Antigen aus der Gruppe, die das Virus der Marek'schen Krankheit, des Infektiösen Bronchitis Virus, des Virus der Newcastle'schen Krankheit oder das Infektiöse Virus der Bursalen Krankheit umfasst.
9. Nukleinsäuresequenz, die mindestens ein zu HVT heterologes Gen oder einen Teil davon umfasst, unter Kontrolle eines Promotors, von DNA-Sequenzen flankiert, die von der wie in Anspruch 1 definierten Insertionsregion des HVT-Genoms abstammen.
10. Rekombinantes DNA-Molekül, das eine Nukleinsäuresequenz gemäss Anspruch 9 umfasst.
11. Wirtszelle, die mit einer Nukleinsäuresequenz gemäss Anspruch 9 oder einem rekombinanten DNA-Molekül gemäss Anspruch 10 transformiert ist.
12. Verfahren zur Herstellung eines rekombinanten HVT gemäss Ansprüchen 1-8, dadurch gekennzeichnet, dass eine entsprechende Zellkultur mit HVT und einem rekombinanten DNA-Molekül gemäss Anspruch 10 cotransfiziert wird.
13. Zellkultur, die mit einem rekombinanten HVT gemäss Ansprüchen 1-8 infiziert ist.
14. Impfstoff, der ein rekombinantes HVT gemäss Ansprüchen 1-8 umfasst.
15. Impfstoff, pharmazeutische oder diagnostische Verbindung, die ein Polypeptid, das von einem rekombinanten HVT gemäss Ansprüchen 1-8 exprimiert wird, umfassen.
16. Verfahren zur Herstellung eines Impfstoffes, dadurch gekennzeichnet, dass das HVT enthaltende Material von einer Zellkultur gemäss Anspruch 13 gewonnen und zu einem Impfstoff verarbeitet wird.
17. Verfahren zur Herstellung eines Impfstoffes, einer pharmazeutischen oder diagnostischen Zusammensetzung, dadurch gekennzeichnet, dass ein Polypeptid, das durch ein rekombinantes HVT gemäss Ansprüchen 1-8 exprimiert wird, zu einem Präparat mit immunisierender, therapeutischer oder diagnostischer Aktivität verarbeitet wird.
18. Antiserum, das Antikörper umfasst, die durch rekombinantes HVT gemäss Ansprüchen 1-8 hervorgerufen werden und die spezifisch daran binden.

Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung eines rekombinanten Truthahnherpesvirus (HVT), dadurch gekennzeichnet, dass eine heterologe Nukleinsäuresequenz in eine Insertionsregion des HVT-Genoms eingeführt wird,
5 die der genomischen Region vom Ende des ORF-1 bis zu und einschliesslich ORF-5 entspricht, die sich innerhalb eines DNA-Fragments des HVT-Genoms befinden, das eine wie in Figur 1 definierte Restriktionsenzymkarte hat oder eine Variante besagter genomischer Region.
2. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass die heterologe Nukleinsäuresequenz in
10 eine Insertionsregion des HVT-Genoms eingeführt wird, die der DNA-Sequenz zwischen Nukleotidposition 82 und 4505 entspricht, definiert durch die DNA-Sequenz, die in SEQ ID NO:1 gezeigt wird oder eine Variante besagter DNA-Sequenz.
3. Verfahren gemäss Ansprüchen 1-2, dadurch gekennzeichnet, dass die Insertionsregion ORF-2 oder
15 ORF-3 entspricht.
4. Verfahren gemäss Anspruch 3, dadurch gekennzeichnet, dass die heterologe Nukleinsäuresequenz in die BglII-Schnittstelle eingebaut ist, die sich in ORF-2 oder ORF-3 befindet.
- 20 5. Verfahren gemäss Ansprüchen 1-4, dadurch gekennzeichnet, dass mindestens ein Teil der Nukleinsäuresequenz des HVT innerhalb der Insertionsregion deletiert ist.
6. Verfahren gemäss Ansprüchen 1-5, dadurch gekennzeichnet, dass die heterologe Nukleinsäuresequenz für ein Polypeptid codiert und unter Kontrolle eines Promotors steht, der die Expression besagter
25 Nukleinsäuresequenz in einer mit besagtem rekombinanten HVT infizierten Zelle reguliert.
7. Verfahren gemäss Ansprüchen 1-6, dadurch gekennzeichnet, dass die heterologe Nukleinsäuresequenz für ein Antigen eines aviären Krankheitserregers codiert.
- 30 8. Verfahren gemäss Anspruch 7, dadurch gekennzeichnet, dass das Antigen aus der Gruppe stammt, die das Virus der Marek'schen Krankheit, das Infektiöse Bronchitis Virus, das Virus der Newcastle'schen Krankheit oder das Infektiöse Virus der Bursalen Krankheit umfasst.
9. Verfahren zur Herstellung einer Nukleinsäuresequenz, das ein Verbinden eines heterologen Gens mit
35 HVT oder eines Teils davon mit flankierenden DNA-Sequenzen unter Kontrolle eines Promotors umfasst, die von der Insertionsregion des HVT-Genoms wie in Anspruch 1 definiert, stammen.
10. Verfahren zur Herstellung eines rekombinanten DNA-Moleküls, das ein Inserieren einer Nukleinsäuresequenz, die gemäss dem Verfahren von Anspruch 9 hergestellt wurde, in einen Vektor umfasst.
40
11. Verfahren zur Herstellung einer transformierten Wirtszelle, das ein Einführen einer gemäss dem Verfahren von Anspruch 9 hergestellten Nukleinsäuresequenz oder eines rekombinanten DNA-Moleküls, das gemäss dem Verfahren von Anspruch 10 hergestellt wurde, in eine Wirtszelle umfasst.
- 45 12. Verfahren zur Herstellung eines rekombinanten HVT, dadurch gekennzeichnet, dass eine geeignete Zellkultur mit HVT-DNA cotransfiziert wird und ein rekombinantes DNA-Molekül, das ein zu HVT heterologes Gen oder einen Teil davon umfasst, unter Kontrolle eines Promotors, flankiert von DNA-Sequenzen, die von der, wie in Anspruch 1 definierten Insertionsregion des HVT-Genoms stammen.
- 50 13. Verfahren zur Herstellung einer mit HVT infizierten Zellkultur, dadurch gekennzeichnet, dass ein Polypeptid, das von einem rekombinanten HVT gemäss dem Verfahren von Ansprüchen 1-8 oder 12 exprimiert wird, zu einer geeigneten Zellkultur gegeben wird.
14. Verfahren zur Herstellung eines Impfstoffes, dadurch gekennzeichnet, dass ein gemäss dem Verfahren
55 der Ansprüche 1-8 oder 12 hergestelltes rekombinantes HVT mit einem pharmazeutisch annehmbaren Träger gemischt wird.

15. Verfahren zur Herstellung eines Impfstoffes, einer pharmazeutischen oder diagnostischen Verbindung, dadurch gekennzeichnet, dass ein Polypeptid, welches von einem rekombinanten HVT exprimiert wird, das gemäss dem Verfahren der Ansprüche 1-8 oder 12 hergestellt wird, in ein Präparat mit immunisierender, therapeutischer oder diagnostischer Aktivität verarbeitet wird.

5

16. Verfahren zur Herstellung eines Antiserums, das Immunisieren eines Tieres mit einem rekombinanten HVT umfasst, das gemäss dem Verfahren der Ansprüche 1-8 oder 12 hergestellt wurde, das Antikörper, die spezifisch daran binden, hervorruft und Sammeln der Antiseren von dem Tier.

10 Revendications

Revendications pour les Etats contractants suivants : BE, CH, DE, FR, GB, IT, LI, NL, SE

1. Herpesvirus recombinant de dindes (HVT) caractérisé en ce qu'il contient une séquence d'acide nucléique hétérologue, ladite séquence d'acide nucléique étant introduite dans une région d'insertion du génome du HVT qui correspond à la région génomique partant de la fin de l'ORF-1 et allant jusqu'à, en incluant, l'ORF-5 localisée dans un fragment d'ADN du génome du HVT présentant la carte de restriction définie par la figure 1 ou une forme variante de ladite région génomique.

15

2. HVT recombinant caractérisé en ce qu'il contient une séquence d'acide nucléique hétérologue, ladite séquence d'acide nucléique étant introduite dans une région d'insertion du génome du HVT qui correspond à la séquence d'ADN, comprise entre les positions des nucléotides 82 et 4505, définie par la séquence d'ADN représentée dans SEQ ID NO:1 ou une forme variante de cette séquence d'ADN.

20

3. HVT recombinant selon les revendications 1-2, caractérisé en ce que la région d'insertion correspond à l'ORF-2 ou l'ORF-3.

25

4. HVT recombinant selon la revendication 3, caractérisé en ce que la séquence d'acide nucléique hétérologue est incorporée dans le site de restriction BglII présent dans l'ORF-2 ou l'ORF-3.

5. HVT recombinant selon les revendications 1 à 4, caractérisé en ce qu'au moins une partie de la séquence d'acide nucléique de HVT dans la région d'insertion est délétée.

30

6. HVT recombinant selon les revendications 1 à 5, caractérisé en ce que la séquence d'acide nucléique hétérologue code pour un polypeptide et est sous le contrôle d'un promoteur régulant l'expression de ladite séquence d'acide nucléique dans une cellule infectée par ledit HVT recombinant.

35

7. HVT recombinant selon les revendications 1-6, caractérisé en ce que la séquence d'acide nucléique hétérologue code pour un antigène d'un agent pathogène aviaire.

8. HVT recombinant selon la revendication 7, caractérisé en ce que l'antigène est obtenu à partir du groupe comprenant le virus de la maladie de Marek, le virus de la bronchite infectieuse, le virus de la maladie de Newcastle ou le virus de la maladie infectieuse des bourses.

40

9. Séquence d'acide nucléique comprenant au moins un gène hétérologue à HVT ou une partie de ce dernier, sous le contrôle d'un promoteur, présentant en position adjacente des séquences d'ADN provenant de la région d'insertion du génome du HVT telle que définie dans la revendication 1.

45

10. Molécule d'ADN recombinant comprenant une séquence d'acide nucléique selon la revendication 9.

11. Cellule hôte transformée par une séquence d'acide nucléique selon la revendication 9 ou une molécule d'ADN recombinant selon la revendication 10.

50

12. Procédé de préparation d'un HVT recombinant selon les revendications 1-8, caractérisé en ce qu'une culture de cellules appropriée est co-transfectée avec de l'ADN du HVT et une molécule d'ADN recombinant selon la revendication 10.

55

13. Culture cellulaire infectée par un HVT recombinant selon les revendications 1-8.

14. Vaccin comprenant un HVT recombinant selon les revendications 1-8.
15. Composition de diagnostic, pharmaceutique, ou de vaccin comprenant un polypeptide exprimé par un HVT recombinant selon les revendications 1-8.
- 5 16. Procédé de préparation d'un vaccin, caractérisé en ce que la matière contenant le HVT est collectée à partir d'une culture cellulaire selon la revendication 13 et est transformée en un vaccin.
- 10 17. Procédé de préparation d'une composition de diagnostic, pharmaceutique, ou de vaccin, caractérisé en ce qu'un polypeptide exprimé par un HVT recombinant selon les revendications 1-8 est transformé en une préparation présentant une activité de diagnostic, thérapeutique, ou immunisante.
18. Un antisérum comprenant des anticorps induits par un HVT recombinant selon les revendications 1-8 et se liant spécifiquement à ce dernier.

15


Revendications pour les Etats contractants suivants : ES, GR

1. Procédé de préparation d'un herpesvirus recombinant de dindes (HVT) caractérisé en ce qu'une séquence d'acide nucléique hétérologue est introduite dans une région d'insertion du génome du HVT qui correspond à la région génomique allant de la fin de l'ORF-1 et jusqu' à, en incluant, l'ORF-5 localisée dans un fragment d'ADN du génome du HVT présentant la carte de restriction définie par la figure 1 ou une forme variante de ladite région génomique.
- 20 2. Procédé selon la revendication 1, caractérisé en ce que la séquence d'acide nucléique hétérologue est introduite dans une région d'insertion du génome du HVT qui correspond à la séquence d'ADN comprise entre les positions des nucléotides 82 et 4505, définie par la séquence d'ADN représentée dans SEQ ID NO:1 ou une forme variante de ladite séquence d'ADN.
- 25 3. Procédé selon les revendications 1-2, caractérisé en ce que la région d'insertion correspond à l'ORF-2 ou l'ORF-3.
- 30 4. Procédé selon la revendication 3, caractérisé en ce que la séquence d'acide nucléique hétérologue est incorporée dans le site de restriction BglII présent dans l'ORF-2 ou l'ORF-3.
- 35 5. Procédé selon les revendications 1 à 4, caractérisé en ce qu'au moins une partie de la séquence d'acide nucléique de HVT dans la région d'insertion est délétée.
6. Procédé selon les revendications 1 à 5, caractérisé en ce que la séquence d'acide nucléique hétérologue code pour un polypeptide et est sous le contrôle d'un promoteur régulant l'expression de ladite séquence d'acide nucléique dans une cellule infectée par ledit HVT recombinant.
- 40 7. Procédé selon les revendications 1-6, caractérisé en ce que la séquence d'acide nucléique hétérologue code pour un antigène d'un agent pathogène aviaire.
- 45 8. Procédé selon la revendication 7, caractérisé en ce que l'antigène est obtenu à partir du groupe comprenant le virus de la maladie de Marek, le virus de la bronchite infectieuse, le virus de la maladie de Newcastle ou le virus de la maladie infectieuse des bourses.
9. Procédé de préparation d'une séquence d'acide nucléique comprenant la liaison d'un gène hétérologue au HVT, ou une partie de ce dernier, sous le contrôle d'un promoteur, pour que soit présent en position adjacente des séquences d'ADN provenant de la région d'insertion du génome du HVT telle que définie dans la revendication 1.
- 50 10. Procédé de préparation d'une molécule d'ADN recombinant comprenant l'insertion d'une séquence d'acide nucléique préparée selon le procédé selon la revendication 9 dans un vecteur.
- 55 11. Procédé de préparation d'une cellule hôte transformée comprenant l'introduction dans une cellule hôte d'une séquence d'acide nucléique préparée selon le procédé selon la revendication 9, ou d'une

molécule d'ADN recombinant préparée selon le procédé selon la revendication 10.

- 5
12. Procédé de préparation d'un HVT recombinant caractérisé en ce qu'une culture de cellules appropriée est co-transfectée avec de l'ADN du HVT et une molécule d'ADN recombinant comprenant un gène hétérologue au HVT ou une partie de ce dernier, sous le contrôle d'un promoteur, présentant en position adjacente des séquences d'ADN dérivées de la région d'insertion du génome de HVT telle que définie dans la revendication 1.
- 10
13. Procédé de préparation d'une culture cellulaire infectée par un HVT recombinant, caractérisé en ce qu'un HVT recombinant préparé selon le procédé selon les revendications 1-8 ou 12 est ajouté à une culture cellulaire appropriée.
- 15
14. Procédé de préparation d'un vaccin caractérisé en ce qu'un HVT recombinant préparé selon le procédé selon les revendications 1-8 ou 12 est mélangé avec un support pharmaceutiquement acceptable.
- 20
15. Procédé de préparation d'une composition de diagnostic, pharmaceutique, ou de vaccin caractérisé en ce qu'un polypeptide exprimé par un HVT recombinant préparé selon le procédé des revendications 1-8 ou 12 est transformé en une préparation présentant une activité immunisante, thérapeutique, ou diagnostique.
- 25
16. Procédé de préparation d'un antisérum comprenant l'immunisation d'un animal avec un HVT recombinant préparé selon le procédé des revendications 1-8 ou 12, la stimulation d'anticorps se liant spécifiquement à ce dernier et la récupération de l'antisérum à partir de l'animal.
- 30
- 35
- 40
- 45
- 50
- 55

Fig 1






Fig 2





Fig 3

Fig 4






Fig 5




Fig 6